Compare Sana Biotechnology Inc (SANA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs VICI Properties Inc — how do they compare? Sana Biotechnology Inc trades at $3.8 (market cap $1.13B), while VICI Properties Inc trades at $26.09 (market cap $28.61B). The key difference: VICI Properties Inc is far larger — about 25.3× Sana Biotechnology Inc's market cap, and VICI Properties Inc pays a 6.93% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VICI | |
|---|---|---|
Market Cap | $1.13B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $5.92 | $33.78 |
52-Week Low | $2.68 | $25.94 |
Enterprise Value | $1.05B | $46.16B |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
VICI Properties trades at $26.07, down slightly by 0.02% on the day. The stock shows a bearish technical signal with moving averages indicating selling pressure, while fundamentals remain solid with a P/E of 10.07 and strong profitability margins. Recent Q2 2026 earnings missed EPS estimates but revenue beat, and the company raised its full-year AFFO guidance. A dividend of $0.45 per share was recently declared, supporting income appeal.
The outlook is mixed; analyst consensus is strongly bullish with a $29.83 price target, but near-term volatility exists due to the Caesars buyout overhang. The 6.6% dividend yield and balance sheet strength provide downside cushion, though high debt and interest expenses pose risks. Upside depends on execution of growth initiatives and stable cash flows from its real estate portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
